Stealth surgical reconstruction startup Tela-Bio raises $45.4M

Tela Bio, a Pennsylvania-based surgical reconstruction startup in stealth mode, raised $45.4 million from 29 investors, according to an SEC filing. According to earlier filings, Tela Bio previously raised $6 million in 2013 and $16.1 million in 2012. The company is reportedly led by Antony Koblish, who previously headed orthobiologics company OrthoVita that was sold to Stryker ($SYK) for $316 million in 2011. Koblish may have turned down a $400,000 annual salary offer to remain with Stryker to found the startup instead. More

Suggested Articles

InterVene secured $15 million to validate its catheter-based treatment for correcting failed one-way valves in the veins of the legs.

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.